The peptide research blog

Most people comparing these peptides assume they're picking a winner. In the published literature they aren't rivals at all: one binds the GHRH receptor, the others mimic ghrelin at GHS-R1a, and research models study them together far more often than head to head.

A peptide's shelf life has almost nothing to do with its sequence and almost everything to do with water. Dry, sealed and frozen, the same molecule can outlast its own paperwork. Dissolved and left at the bench, it may be finished in days.

Most international peptide orders that stall at the border don't fail because the compound is restricted. They fail because the paperwork didn't match the parcel. Customs officers read documents, not molecules — and that single distinction decides whether a research shipment clears in days or sits in a warehouse for weeks.

Hundreds of papers exist on BPC-157, and almost none of them involve humans. The published record is overwhelmingly rat and mouse work from a narrow set of authors, with no completed controlled human efficacy trial, no long-term toxicology package, and no canine evidence at all.

Most research peptides don't degrade sitting in cold storage. They degrade in the thirty seconds a chilled vial spends open on a warm bench. Here's the temperature logic behind refrigerated, frozen, and ultra-low archival storage, and the freezer feature that quietly ruins long-term samples.

The fastest way to wreck a tub of collagen powder isn't a hot car. It's the scoop left sitting inside it. Hydrolyzed collagen pulls water straight out of the air, and moisture degrades it long before warmth does.

The legality of a research peptide has almost nothing to do with the molecule inside the vial. Two suppliers can ship the identical compound, and only one of them is breaking federal law. The difference is the label, the claims, and documented intended use.

Nothing in UK law bans research peptides as a class. What decides legality is the label, the claim and the buyer, not the molecule. The same logic shapes how Australia's TGA and the Thai FDA treat an identical vial, with very different consequences at the border.

Ipamorelin is not HGH, and MK-677 is not a peptide. Both signal the pituitary through the same ghrelin receptor, yet their half-lives differ enough to change what a study can actually measure. Here is how they line up against sermorelin, tesamorelin and recombinant HGH.

A vial can be filled and shipped from a US address while the crude peptide inside was synthesized overseas. That gap is legal, invisible on the label, and the single biggest reason two suppliers both claiming domestic origin hand you very different material.

Most researchers comparing these two assume they're weighing up two peptides. They aren't. One is a 16-amino-acid mitochondrial-derived peptide, the other a synthetic nuclear receptor agonist, and that single structural fact changes storage, solubility and assay design before any data gets collected.

The biggest source of variance in growth hormone secretagogue work isn't purity, it's the freezer. Here's what the GHRH plus GHRP literature actually reports about the CJC-1295 no DAC and ipamorelin blend, how tesamorelin stacks differ, and what a certificate of analysis should show before a vial enters a study.

A vial that arrives cold can still be ruined in the first ten seconds after you open it. Cold chain shipping for peptides is less about how frozen the box is and more about moisture, mechanical shock, and what happens after the courier leaves.

Most international peptide orders that fail never fail in the lab. They fail in a bonded warehouse at ambient temperature, with no paperwork explaining what the vial contains. Here is how import rules and customs handling differ across Canada, the UK, the EU, Australia, China and beyond.

Search BPC-159 in the scientific literature and you find nothing: no sequence, no CAS number, no indexed studies. BPC-157 has all three. Most of the confusion here is really a salt-form question, and the answer sits on the certificate of analysis, not the product page.

Most three-way comparisons of these compounds quietly compare the wrong molecule. CJC-1295 names two different peptides with half-lives that differ by orders of magnitude, and until you separate them, nothing else in the comparison holds up. Here is what the published research actually reports.

Two vials, one molecule, one linker. The gap between a CJC-1295 No DAC research peptide and the DAC version isn't potency at the receptor, it's how long the compound stays in circulation. That single difference reshapes sampling schedules, assay windows and study design.

Peptides rarely fail from heat or age. They fail from the liquid they land in. Strong oxidizers, free metal ions, wrong-pH buffers and a second peptide sharing the vial do more damage than storage ever will, and none of it changes how the solution looks.

Bulk peptide procurement rarely fails on price. It fails on traceability. Two vials can both report 99% purity and still differ in net peptide content, counterion load, and residual moisture. Here is how labs vet wholesale suppliers, read batch certificates, and structure a quote request.

Epitalon and epithalon are not two compounds. They are one tetrapeptide with two spellings. DSIP is something else entirely: a nine-residue peptide out of 1970s sleep research with its own contested history. Here is how these pineal-adjacent peptides actually differ on paper and in the lab.

Ipamorelin's most-cited result isn't how much growth hormone it released. It's what it left alone. The published literature is narrower than the marketing built around it, and understanding the difference changes how a laboratory sources, verifies, and designs work with this pentapeptide.

A vial that spent a warm weekend at 25°C looks identical to one held steady at -20°C. Lyophilized powder and reconstituted solution need completely different temperatures, and colder is not always safer. Here are the numbers, in both Celsius and Fahrenheit.

Peptide degradation usually starts when a cold vial gets opened too fast, not when a freezer runs a few degrees warm. Lyophilized powder, reconstituted solution, and pre-mixed liquid each need different handling. Here are the temperature ranges, the four degradation pathways, and the mistakes labs repeat.

One of these two compounds has been on pharmacy shelves since 2010. The other has never been approved anywhere in the world. Comparing liraglutide vs retatrutide is less a head-to-head and more a snapshot of how incretin pharmacology changed in fifteen years.

Selank was not built as a nootropic. It was built as a stability fix: a tuftsin fragment with a Pro-Gly-Pro tail added so enzymes take longer to break it down. Here is what the published literature reports, and what a certificate of analysis should actually show.

The thing that gets research peptides stopped at a border is almost never the peptide itself. It's an unlabelled vial, a missing certificate of analysis, and a syringe packed beside it. Format and paperwork decide the outcome, not chemistry.

The head-to-head route comparison everyone searches for does not exist in the peer-reviewed literature. Nearly all foundational BPC-157 rodent work used intraperitoneal or intragastric delivery, not the two injection routes argued about online. Here is what the research genuinely supports, and what is being invented.

IGF-1 LR3 is not a stronger version of Sermorelin. One tells the pituitary to release its own growth hormone in pulses; the other skips the pituitary entirely and binds the IGF-1 receptor directly. Here is how the mechanisms, and the ghrelin-receptor compounds, actually separate.

Most peptide vendor reviews rate shipping speed, not purity. The only line in a review you can independently check is a lot number, because it unlocks the batch certificate of analysis behind it. Here is how to read supplier claims against real analytical data.

Scale weight is the worst possible way to compare these compounds. Retatrutide acts on gut hormone receptors and lowers total mass; androgens bind a nuclear receptor and add contractile tissue. Two opposite arrows, one number. Here is how the classes actually separate.

The airport checkpoint is almost never where research peptides get ruined. The cargo hold is. Screening rules are the easy part of flying with vials; temperature control, freeze-thaw cycling and delayed baggage are what actually cost researchers their material.

There is no such thing as a GLP-3 receptor. The label attached to retatrutide across the research-supply market is shorthand for something more interesting: one peptide engineered to hit three receptors at once. Here is what the published trial literature actually reports.

The purity percentage on a peptide label is the least useful number a supplier gives you. What separates real synthesis partners from repackagers is lot-matched, third-party documentation: the chromatogram, the mass spectrum, the batch number. Here is the checklist labs actually use to tell them apart.

A 99% purity claim is the easiest number on a peptide listing to print and the hardest thing to verify. Chromatographic purity and net peptide content measure two completely different things, and the gap between them quietly breaks your concentration math. Here is how to read the specifications properly.

A single dose of CJC-1295 with DAC kept IGF-1 elevated for nine to eleven days in a published human trial. That sounds decisive until you ask what the trial actually measured. Biomarkers moved. Clinical endpoints were never tested.

Semax and modafinil get grouped together constantly, yet they share almost nothing mechanistically. One is a synthetic ACTH fragment studied for BDNF expression; the other is a scheduled wakefulness-promoting pharmaceutical. That distinction changes everything about how each is studied, sourced and regulated.

Semax was never designed as a nootropic. It's a trimmed fragment of adrenocorticotropic hormone with the steroid-releasing part engineered out and a proline tail bolted on so enzymes can't dismantle it. That tail, not the fragment, is the design breakthrough most summaries skip entirely.

The purity percentage in a peptide listing is the least useful number on the page. A supplier can print 99% without naming the method, the lot, or the lab that ran it. Here's what verified researchers actually check before a vial goes near an assay.

MK-677 isn't a peptide at all, which is exactly why storing it like one wastes freezer space and misses the real risk. Small molecules, lyophilised powders, and copper complexes each degrade through different pathways. Here's the compound-by-compound reference researchers actually need.

Most ambient exposure worry is misplaced. A sealed lyophilized vial stays chemically quiet at room temperature for days, while the same peptide in solution degrades in a fraction of that time. The real damage usually comes from condensation and repeated freeze-thaw cycles, not a warm shipping lane.

The phrase 'lab tested' on a peptide listing carries no information by itself. What matters is who ran the assay, which production lot it covers, and whether you can read the chromatogram yourself. Here is how researchers verify a supplier before the first order.

The number most people want doesn't exist in the form they want it. GHK-Cu is a coordination complex, which means its clearance is two separate clocks: the tripeptide's and the copper's. Here's what the published literature actually supports, and what it doesn't.

A vial labeled BPC-157 and TB-500 40mg could be a 20/20 split or a 10/30 split, and the price rarely tells you which. Blend ratios, net peptide content and batch certificates decide what a lab actually receives.

Almost everything published on BPC-157 comes from animal models, and a large share of it traces back to a single university group. That one fact reshapes how researchers should read the literature, evaluate suppliers, and interpret the mechanism claims circulating online.

Two vials of MOTS-c can both read 99% on the label and still hold different amounts of actual peptide. Purity and peptide content are separate numbers, and only one of them tells you what's really in the vial. Here's how to read the difference before you buy.

Two vials labelled GHK-Cu can differ by more than purity — one may be a copper-saturated complex, the other a partially uncomplexed tripeptide. The label rarely says which. Here is what separates verified research material from an unverifiable powder.

MK 677 isn't a SARM, isn't a steroid and isn't even a peptide, which is why most vendor listings get its classification wrong. Here is what the compound actually is, how it is synthesised, where it stands legally, and what the published trial literature reported.

The spray bottle isn't a new formulation, a stronger version, or an upgrade. It's packaging built around a weakness: Semax is a seven-residue peptide that falls apart in minutes. Here's the chemistry, the published record, and the regulatory reality behind both Semax and Selank.

APGWamide isn't a human hormone at all. It's a four-residue molluscan neuropeptide, and the search volume behind it comes from researchers who need sequence and purity data, not a shopping page. Here's how to read what a research catalog is actually telling you.

Two vials sold under the same three characters can hold two chemically different molecules. One is the full 43-residue protein. The other is a short synthetic construct built around residues 17 to 23. The certificate of analysis, not the product page, tells you which one arrived.

Most peptide orders that disappoint UK researchers were compromised before they arrived, not after. Price per milligram is the wrong first filter. Net peptide content, salt form, batch-matched certificates of analysis and customs handling decide what actually lands on your bench.

The modification that makes IGF-1 LR3 potent in cell culture is the same one that removes the body's natural brake on growth signalling. Here are the reported adverse effects, the regulatory position and the anti-doping rules, separated cleanly from forum anecdote.

Peptides aren't harvested from anything. They're built backwards, one amino acid at a time, on a plastic bead the size of a dust speck. Understanding that assembly line explains why two vials with identical labels can behave very differently in a lab.

Federal law has no category called peptides. Two vials holding the exact same molecule can sit on opposite sides of the law based on nothing but the label. Here's how classification, intended use, and marketing claims decide what's legal.

Most people assume somebody already ran the experiment. Search the indexed literature for a study that gave SS-31 and MOTS-c together in the same model and you won't find one. Here's what each compound actually does, and why the combination is still an open question.

The potency figure quoted under every before-and-after post came from bioreactor cell culture, not a human trial. IGF 1 LR3 results reported on Reddit and bodybuilding forums sit almost entirely outside the controlled research record. Here is exactly where the evidence stops.

Copper peptide failures are usually chemistry failures, not peptide failures. GHK-Cu holds its copper ion only inside a narrow pH window, and direct vitamin C, EDTA and thiol reducing agents can strip it. Here is what pairs cleanly, what breaks the complex, and why colour matters.

Most problems with multi-compound research blends never start at the bench. They start on the certificate. A single aggregate purity figure printed on one line tells a researcher almost nothing about which component in a three-peptide vial is intact and which one degraded in transit.

Retatrutide gets filed under growth hormone peptides constantly, and the label is wrong at the level of the molecule. It shares no sequence, no receptor and no signalling pathway with somatropin. Here is the mechanism-versus-mechanism breakdown research groups actually need.

The strongest evidence for SNAP-8 comes from cell assays, not intact skin. Its SNARE-competition mechanism is well described, but the peptide's target sits below the dermis in muscle tissue. That distance, not purity or concentration, is the real bottleneck researchers keep underestimating.